Enzo Biochem (ENZ) 10-Q 11 Jun 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2018	Jun. 01, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		47,165,942
Amendment Flag	false
Entity Central Index Key	316,253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Apr. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Current assets:
Cash and cash equivalents	$ 62,556	$ 64,167
Accounts receivable, net of allowances	14,407	15,180
Inventories	7,278	7,047
Prepaid expenses and other	2,175	2,690
Total current assets	86,416	89,084
Property, plant and equipment, net	7,953	7,901
Goodwill	7,452	7,452
Intangible assets, net	2,149	2,895
Other assets	1,481	333
Total assets	105,451	107,665
Current liabilities:
Accounts payable – trade	8,250	10,350
Accrued liabilities	9,795	6,720
Other current liabilities	623	740
Total current liabilities	18,668	17,810
Other liabilities	404	983
Total liabilities	19,072	18,793
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,161,942 at April 30, 2018 and 46,506,176 at July 31, 2017	472	465
Additional paid-in capital	330,517	328,294
Accumulated deficit	(246,457)	(241,900)
Accumulated other comprehensive income	1,847	2,013
Total stockholders’ equity	86,379	88,872
Total liabilities and stockholders’ equity	$ 105,451	$ 107,665

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Apr. 30, 2018	Jul. 31, 2017
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	47,161,942	46,506,176
Common Stock, shares outstanding	47,161,942	46,506,176

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Revenues:
Revenues	$ 25,630	$ 27,089	$ 80,258	$ 79,633
Operating costs and expenses:
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Total operating costs and expenses	28,428	27,348	86,710	82,232
Operating loss	(2,798)	(259)	(6,452)	(2,599)
Other income (expense):
Interest	227	115	569	240
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Loss before income taxes	(3,016)	(71)	(5,654)	(2,598)
Benefit for income taxes		0	1,097	0
Net loss	$ (3,016)	$ (71)	$ (4,557)	$ (2,598)
Net loss per common share:
Basic and diluted (in Dollars per share)	$ (0.06)	$ 0	$ (0.10)	$ (0.06)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	47,073	46,367	46,895	46,310
Clinical Laboratory Services [Member]
Revenues:
Revenues	$ 18,137	$ 19,584	$ 58,001	$ 56,979
Operating costs and expenses:
Cost of Revenues	10,995	11,334	34,767	33,282
Product [Member]
Revenues:
Revenues	7,415	7,312	21,618	21,721
Operating costs and expenses:
Cost of Revenues	3,562	3,582	10,828	10,411
Royalty and License Fees [Member]
Revenues:
Revenues	$ 78	$ 193	$ 639	$ 933

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Net loss	$ (3,016)	$ (71)	$ (4,557)	$ (2,598)
Other comprehensive income (loss):
Foreign currency translation adjustments	329	(116)	(166)	122
Comprehensive loss	$ (2,687)	$ (187)	$ (4,723)	$ (2,476)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Apr. 30, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2017	$ 465		$ 328,294	$ (241,900)	$ 2,013	$ 88,872
Balance, Shares (in Shares) at Jul. 31, 2017	46,506,176
Net loss for the period ended April 30, 2018				(4,557)		(4,557)
Cashless options exercise	$ 4	$ (1,014)	1,010
Cashless options exercise, Shares (in Shares)	340,898	106,911
Vesting of restricted stock, Shares (in Shares)	2,562
Exercise of stock options	$ 3		828			$ 831
Exercise of stock options, Shares (in Shares)	274,726					615,624
Share-based compensation charges			617			$ 617
Issuance of common stock and treasury stock for employee 401(k) plan match		$ 1,014	(232)			782
Issuance of common stock and treasury stock for employee 401(k) plan match, Shares (in Shares)	37,580	(106,911)
Foreign currency translation adjustments					(166)	(166)
Balance at Apr. 30, 2018	$ 472		$ 330,517	$ (246,457)	$ 1,847	$ 86,379
Balance, Shares (in Shares) at Apr. 30, 2018	47,161,942

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Cash flows from operating activities:
Net loss	$ (4,557)	$ (2,598)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment	1,608	1,552
Amortization of intangible assets	742	1,140
Provision for uncollectible accounts receivable	1,989	1,968
Share-based compensation charges	617	601
Accrual for share-based 401(k) employer match expense	630	552
Foreign exchange (gain) loss	(149)	267
Changes in operating assets and liabilities:
Accounts receivable	(1,233)	(3,192)
Inventories	(257)	(213)
Prepaid expenses and other	513	195
Accounts payable – trade	(2,126)	(459)
Accrued liabilities, other current liabilities and other liabilities	2,846	(1,707)
Other assets	(1,098)
Total adjustments	4,082	704
Net cash used in operating activities	(475)	(1,894)
Cash flows from investing activities:
Capital expenditures	(1,626)	(1,424)
Security deposits and other	(51)	6
Net cash used in investing activities	(1,677)	(1,418)
Cash flows from financing activities:
Proceeds from borrowings under Credit Agreement		40,694
Repayments under Credit Agreement		(42,250)
Installment loan and capital lease obligation payments	(299)	(428)
Proceeds from exercise of stock options	831	159
Net cash provided by (used in) financing activities	532	(1,825)
Effect of exchange rate changes on cash and cash equivalents	9	(13)
Decrease in cash and cash equivalents	(1,611)	(5,150)
Cash and cash equivalents - beginning of period	64,167	67,777
Cash and cash equivalents - end of period	$ 62,556	$ 62,627

Basis of Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2018
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2018, the consolidated statements of operations and comprehensive income (loss) for the three and nine month ended April 30, 2018 and 2017, the consolidated statements of cash flows for the nine months ended April 30, 2018 and 2017 and the consolidated statement of stockholders’ equity for the nine months ended April 30, 2018 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2017 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2017 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2018. Effect of New Accounting Pronouncements Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting Pronouncements Issued but Not Yet Adopted In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606 The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows. In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842) We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases. We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative. In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

Net income (loss) per share

Net income (loss) per share	9 Months Ended
	Apr. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and nine months ended April 30, 2018 and 2017 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and nine months ended April 30, 2018, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 431,000 and 694,000, respectively, because their effect would be antidilutive. For the three and nine months ended April 30, 2017, approximately 987,000 and 865,000 weighted average stock options were excluded from the calculation of diluted weighted average shares outstanding because their effect would be antidilutive. For the three and nine months ended April 30, 2018, the effect of approximately 581,000 and 194,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2017, the effect of approximately zero and 165,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	9 Months Ended
	Apr. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows For the nine months ended April 30, 2018 and 2017, income taxes paid by the Company were $65 and $1,021, respectively . For the nine months ended April 30, 2018 and 2017, interest paid by the Company was $61 and $99, respectively. For the nine months ended April 30, 2018 and 2017, the Company financed $0 and $69 respectively, in machinery and transportation equipment under installment loans. During the nine months ended April 30, 2018 certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. During the nine months ended April 30, 2018, the Company contributed its treasury stock and issued common stock in connection with its share-based 401(k) employer match in the amount of $782. For the 2017 period, the Company issue shares of common stock in the amount of $724.

Inventories

Inventories	9 Months Ended
	Apr. 30, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventories Inventories consist of the following: April 30, July 31, Raw materials $ 817 $ 852 Work in process 2,065 1,905 Finished products 4,396 4,290 $ 7,278 $ 7,047

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Apr. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 5 – Goodwill and intangible assets At April 30, 2018 and July 31, 2017, the Company’s carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Net July 31, 2017 $ 27,436 $ (24,541 ) $ 2,895 Amortization expense — (742 ) (742 ) Foreign currency translation 2 (6 ) (4 ) April 30, 2018 $ 27,438 $ (25,289 ) $ 2,149 Intangible assets, all finite lived, consist of the following: April 30, 2018 July 31, 2017 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,971 ) $ 56 $ 11,027 $ (10,951 ) $ 76 Customer relationships 11,892 (9,799 ) 2,093 11,881 (9,083 ) 2,798 Website and acquired content 1,010 (1,010 ) — 1,011 (1,011 ) — Licensed technology and other 492 (492 ) — 484 (463 ) 21 Trademarks 3,017 (3,017 ) — 3,033 (3,033 ) — Total $ 27,438 $ (25,289 ) $ 2,149 $ 27,436 $ (24,541 ) $ 2,895 At April 30, 2018, information with respect to intangibles assets acquired is as follows: Useful life Weighted average Customer relationships 8 -15 years 2.5 years Other intangibles 10 years 1.5 years At April 30, 2018, the weighted average remaining useful life of intangible assets is approximately two years.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Apr. 30, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 6 – Accrued Liabilities Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 4,343 $ 4,092 Legal fee expense 2,401 599 Professional fees 764 442 Research and development — 143 Other 2,287 1,444 $ 9,795 $ 6,720 At April 30, 2018, other accrued liabilities primarily include $400 for a legal settlement.

Other Liabilities

Other Liabilities	9 Months Ended
	Apr. 30, 2018
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 7 – Other Liabilities Other liabilities consist of the following: April 30, July 31, Capital lease obligations, net of short term $ 397 $ 551 Accrued legal settlement — 410 Installment loans, net of short term 7 22 $ 404 $ 983 As of April 30, 2018, future minimum payments under the capital leases, net of interest of $75 aggregates $570 including a short term debt portion of $173 included in other current liabilities. Future minimum payments under the installment loans aggregate $44, including a short term portion of $37 included in other current liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity Offering SM On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017. During the nine months ended April 30, 2018 and during fiscal 2017, the Company did not sell any shares of Common Stock under the Sales Agreement. Treasury stock During the nine months ended April 30, 2018, certain officers of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares, as treasury stock. All of the treasury shares were used in the share-based 401(k) employer match made during the nine months ended April 30, 2018. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Plan”). The 2011 Incentive Plan, which is the only plan from which awards may be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. At the 2017 annual meeting, shareholders approved the amendment and restatement of the 2011 Plan, including an increase in the number of shares of common stock authorized for grant under the 2011 Plan, from 3 million shares to 5 million shares. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2018 2017 2018 2017 Stock options $ 202 $ 204 $ 609 $ 586 Restricted stock 2 5 8 15 $ 204 $ 209 $ 617 $ 601 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2018 2017 2018 2017 Cost of clinical laboratory services $ — $ 2 $ — $ 5 Selling, general and administrative 204 207 617 596 $ 204 $ 209 $ 617 $ 601 No excess tax benefits were recognized during the nine month periods ended April 30, 2018 and 2017. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2018: Options Weighted Weighted Aggregate Outstanding at July 31, 2017 2,130,995 $ 4.26 Awarded 117,580 $ 8.36 Exercised (615,624 ) $ 2.99 $ 5,896 Cancelled or expired (29,334 ) $ 5.94 Outstanding at end of period 1,603,617 $ 5.02 2.6 years $ 4,344 Exercisable at end of period 1,168,489 $ 4.25 1.2 years $ 2,261 As of April 30, 2018, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.9 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is fourteen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows: Awards Weighted Outstanding at July 31, 2017 7,436 $ 4.45 Awarded — — Vested (2,562 ) $ (5.51 ) Forfeited (386 ) (5.62 ) Unvested at end of period 4,488 $ 2.97 The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2018, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-two months. The fair value of the awards that vested during the nine months ended April 30, 2018 and 2017 was $22 and $19, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 2,266,800 shares as of April 30, 2018. During the nine months ended April 30, 2018, the Company contributed $782 to match its employees’ 401(k) contributions with 106,911 shares of treasury stock and by issuing 37,580 shares of its common stock, representing the fair value of the shares at the match date, and adjusted treasury stock, common stock and additional paid in capital by the same amount. During the nine months ended April 30, 2017, the Company contributed $724 to match its employees’ 401(k) contributions by issuing 91,541 shares of its common stock, representing the fair value of the shares at the match date, and adjusted common stock and additional paid in capital by the same amount.

Income taxes

Income taxes	9 Months Ended
	Apr. 30, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 9 – Income taxes On December 22, 2017, legislation commonly known as the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. The Company calculated its best estimate of the impact of the Act in accordance with its understanding of the Act and guidance available as of the date of this filing and recorded $1.1 million as an income tax benefit in the nine months ended April 30, 2018, the period in which the legislation was enacted, related to a credit for alternative minimum taxes (AMT) paid in prior periods. A provisional amount related to the remeasurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was fully offset by an equivalent adjustment to the deferred tax valuation allowance. No provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings was deemed necessary. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has determined that the $1.1 million income tax benefit, which relates to the AMT credit, is a provisional amount and a reasonable estimate at April 30, 2018. The Company’s effective tax rate benefit for the three and nine months ended April 30, 2018 was zero and 24.1%, respectfully and was based on the refundable federal AMT credit. There was no tax provision or benefit for the 2017 periods. The Company’s effective tax rate for all periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

Segment reporting

Segment reporting	9 Months Ended
	Apr. 30, 2018
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 10 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. When recognized, legal settlements, net represents activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2017. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2018 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,137 — — — $ 18,137 Product revenues — $ 7,415 — — 7,415 Royalty and license fee income — 78 — — 78 18,137 7,493 — — 25,630 Operating costs and expenses: Cost of clinical laboratory services 10,995 — — — 10,995 Cost of product revenues — 3,562 — — 3,562 Research and development — 576 $ 223 — 799 Selling, general and administrative 6,252 2,974 — $ 1,799 11,025 Provision for uncollectible accounts receivable 400 (4 ) — — 396 Legal fee expense 25 19 — 1,607 1,651 Total operating costs and expenses 17,672 7,127 223 3,406 28,428 Operating income (loss) 465 366 (223 ) (3,406 ) (2,798 ) Other income (expense): Interest (22 ) 12 — 237 227 Other 15 2 — — 17 Foreign exchange loss — (462 ) — — (462 ) Income (loss) before income taxes $ 458 $ (82 ) $ (223 ) $ (3,169 ) $ (3,016 ) Depreciation and amortization included above $ 437 $ 358 $ — $ 20 $ 815 Share-based compensation included in above: Selling, general and administrative 26 $ 17 — $ 161 204 Total $ 26 $ 17 $ — $ 161 $ 204 Capital expenditures $ 465 $ 96 $ — $ — $ 561 Three months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 19,584 — — — $ 19,584 Product revenues — $ 7,312 — — 7,312 Royalty and license fee income — 193 — — 193 19,584 7,505 — — 27,089 Operating costs and expenses: Cost of clinical laboratory services 11,334 — — — 11,334 Cost of product revenues — 3,582 — — 3,582 Research and development — 552 $ 214 — 766 Selling, general and administrative 6,118 2,745 — $ 1,671 10,534 Provision for uncollectible accounts receivable 650 (30 ) — — 620 Legal fee expense 4 42 — 466 512 Total operating costs and expenses 18,106 6,891 214 2,137 27,348 Operating income (loss) 1,478 614 (214 ) (2,137 ) (259 ) Other income (expense): Interest (28 ) 12 — 131 115 Other 7 (98 ) — 17 (74 ) Foreign exchange gain — 147 — — 147 Income (loss) before income taxes $ 1,457 $ 675 $ (214 ) $ (1,989 ) $ (71 ) Depreciation and amortization included above $ 390 $ 423 $ — $ 37 $ 850 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 38 $ 23 — $ 146 207 Total $ 40 $ 23 $ — $ 146 $ 209 Capital expenditures $ 483 $ 252 $ — $ — $ 735 Nine months ended April 30, 2018 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 58,001 — — — $ 58,001 Product revenues — $ 21,618 — — 21,618 Royalty and license fee income — 639 — — 639 58,001 22,257 — — 80,258 Operating costs and expenses: Cost of clinical laboratory services 34,767 — — — 34,767 Cost of product revenues — 10,828 — — 10,828 Research and development — 1,690 $ 668 — 2,358 Selling, general and administrative 18,454 8,487 — $ 6,045 32,986 Provision for uncollectible accounts receivable 2,000 (11 ) — — 1,989 Legal fee expense 46 47 — 3,689 3,782 Total operating costs and expenses 55,267 21,041 668 9,734 86,710 Operating income (loss) 2,734 1,216 (668 ) (9,734 ) (6,452 ) Other income (expense): Interest (70 ) 35 — 604 569 Other 32 10 — 44 86 Foreign exchange gain — 143 — — 143 Income (loss) before income taxes $ 2,696 $ 1,404 $ (668 ) $ (9,086 ) $ (5,654 ) Depreciation and amortization included above $ 1,254 $ 1,039 $ — $ 57 $ 2,350 Share-based compensation included in above: Selling, general and administrative 86 $ 61 — $ 470 617 Total $ 86 $ 61 $ — $ 470 $ 617 Capital expenditures $ 1,459 $ 167 $ — $ — $ 1,626 Nine months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 56,979 — — — $ 56,979 Product revenues — $ 21,721 — — 21,721 Royalty and license fee income — 933 — — 933 56,979 22,654 — — 79,633 Operating costs and expenses: Cost of clinical laboratory services 33,282 — — — 33,282 Cost of product revenues — 10,411 — — 10,411 Research and development — 1,695 $ 376 — 2,071 Selling, general and administrative 17,967 8,596 — $ 6,683 33,246 Provision for uncollectible accounts receivable 1,910 58 — — 1,968 Legal fee expense 105 70 — 1,079 1,254 Total operating costs and expenses 53,264 20,830 376 7,762 82,232 Operating income (loss) 3,715 1,824 (376 ) (7,657 ) (2,599 ) Other income (expense): Interest (85 ) 34 — 291 240 Other 126 (98 ) — 41 69 Foreign exchange loss — (308 ) — — (308 ) Income (loss) before income taxes $ 3,756 $ 1,452 $ (376 ) $ (7,430 ) $ (2,598 ) Depreciation and amortization included above $ 1,185 $ 1,432 $ — $ 75 $ 2,692 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 74 $ 49 — $ 473 596 Total $ 79 $ 49 $ — $ 473 $ 601 Capital expenditures $ 1,070 $ 354 $ — $ — $ 1,424

Contingencies

Contingencies	9 Months Ended
	Apr. 30, 2018
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 11 – Contingencies The Company is engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. In December 2013, the Court granted in part and denied in part Roche’s summary judgment motion. In October 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by the end of January 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On October 2, 2017, the Court issued its claim construction ruling. On May 11, 2018, the Court issued a revised scheduling order which required the completion of expert discovery by July 13, 2018 and scheduled a conference on August 17, 2018 that will function as a pre-trial conference or a pre-motion conference. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them. There are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware (“the Court”) alleging patent infringement against various companies. On June 28, 2017, the Court issued an opinion in the Gen-Probe case, granting Gen-Probe’s motion for summary judgment that the asserted claims of the ’180 patent are invalid for nonenablement. The Court entered final judgment of invalidity of the asserted claims of the ‘180 patent on July 19, 2017 in the Gen-Probe and Hologic cases. The Court entered partial final judgment of invalidity of the asserted claims of the ‘180 patent and stayed the remainder of the cases in the Becton Dickinson and Roche cases on July 31, 2017 and August 2, 2017, respectively. The Company filed notices of appeal in each of the Gen-Probe, Hologic, Becton Dickinson, and Roche cases, which were docketed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). In the Abbott case, the parties agreed that the Court’s summary judgment ruling in the Gen-Probe case invalidated all of the ’180 patent claims asserted against the Abbott Defendants. On August 15, 2017, the Court granted Abbott’s motion for summary judgment that the asserted claims of the ’405 patent are invalid for nonenablement. On September 1, 2017, the Court entered final judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents for nonenablement in the Abbott case. Enzo subsequently filed a notice of appeal in the Abbott case on September 14, 2017. The Federal Circuit docketed the appeal on September 15, 2017. The Federal Circuit consolidated the appeals from the Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche litigations (“Consolidated Appeals”). We disagree with the Court’s invalidity decisions regarding the ‘180 and ‘405 patents in the pending cases as set forth in our opening brief in the Consolidated Appeals pending in the Federal Circuit filed on November 28, 2017. In the Consolidated Appeals, we have asked the Federal Circuit to reverse the Court’s grants of final and summary judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents and to remand the cases against Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche to the Court. Briefing is now complete in the Consolidated Appeals. The parties await the Federal Circuit’s scheduling of an oral argument date for the Consolidated Appeals. In the other two cases involving Hologic, one of the cases is stayed (Hologic II), while the other case (Hologic III) that involves the ‘581 patent is proceeding under the Court’s scheduling order with fact and expert discovery deadlines through September 2018, a summary judgment hearing date in April 2019, and a trial date in September 2019. In Hologic III, the Court granted Enzo’s motion to amend its complaint to add two new defendants, Grifols Diagnostic Solutions, Inc. and Grifols, S.A, to that case. Grifols, S.A. has moved to dismiss for lack of personal jurisdiction; briefing on that motion is complete but the Court has not set a date for oral argument. The parties have completed claim construction briefing, and a claim construction hearing is scheduled for July 2, 2018. Regarding Hologic’s petition requesting institution of an inter partes There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Apr. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting
Pronouncements Issued but Not Yet Adopted [Policy Text Block]	Pronouncements Issued but Not Yet Adopted In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606 The standard will be effective for our fiscal year beginning August 1, 2018 and its interim periods. We are not early adopting. We expect to use the full retrospective method upon adoption by applying the standard to each prior reporting period presented. We continue to evaluate the expected impact of the standard. Based on our preliminary assessment of the standard, we expect that the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be considered an implicit price concession in determining net revenues. Accordingly, we expect to report the estimate of uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. The adoption of this standard will also result in increased disclosure, including qualitative and quantitative disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However, the adoption of this standard is not expected to have a material impact on our financial position or cash flows. In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842) We believe the adoption of this standard would materially impact our consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated balance sheets if we record the right of use assets and related lease liabilities for our existing operating leases. We will recognize expense in the consolidated statement of operations similar to current lease accounting, in the cost of sales and selling, general and administrative. In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting In May 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 40% and 38% of the Clinical Labs segment net revenue for the three months ended April 30, 2018 and 2017 respectively, and 39% and 38% for the nine months ended April 30, 2018 and 2017, respectively.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Apr. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: April 30, July 31, Raw materials $ 817 $ 852 Work in process 2,065 1,905 Finished products 4,396 4,290 $ 7,278 $ 7,047

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Apr. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Net July 31, 2017 $ 27,436 $ (24,541 ) $ 2,895 Amortization expense — (742 ) (742 ) Foreign currency translation 2 (6 ) (4 ) April 30, 2018 $ 27,438 $ (25,289 ) $ 2,149
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite lived, consist of the following: April 30, 2018 July 31, 2017 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,971 ) $ 56 $ 11,027 $ (10,951 ) $ 76 Customer relationships 11,892 (9,799 ) 2,093 11,881 (9,083 ) 2,798 Website and acquired content 1,010 (1,010 ) — 1,011 (1,011 ) — Licensed technology and other 492 (492 ) — 484 (463 ) 21 Trademarks 3,017 (3,017 ) — 3,033 (3,033 ) — Total $ 27,438 $ (25,289 ) $ 2,149 $ 27,436 $ (24,541 ) $ 2,895
Schedule of Useful Lives For Acquisitions [Table Text Block]	At April 30, 2018, information with respect to intangibles assets acquired is as follows: Useful life Weighted average Customer relationships 8 -15 years 2.5 years Other intangibles 10 years 1.5 years

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Apr. 30, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 4,343 $ 4,092 Legal fee expense 2,401 599 Professional fees 764 442 Research and development — 143 Other 2,287 1,444 $ 9,795 $ 6,720

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Apr. 30, 2018
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	Other liabilities consist of the following: April 30, July 31, Capital lease obligations, net of short term $ 397 $ 551 Accrued legal settlement — 410 Installment loans, net of short term 7 22 $ 404 $ 983

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Apr. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2018 2017 2018 2017 Stock options $ 202 $ 204 $ 609 $ 586 Restricted stock 2 5 8 15 $ 204 $ 209 $ 617 $ 601
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2018 2017 2018 2017 Cost of clinical laboratory services $ — $ 2 $ — $ 5 Selling, general and administrative 204 207 617 596 $ 204 $ 209 $ 617 $ 601
Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity during the nine month period ended April 30, 2018: Options Weighted Weighted Aggregate Outstanding at July 31, 2017 2,130,995 $ 4.26 Awarded 117,580 $ 8.36 Exercised (615,624 ) $ 2.99 $ 5,896 Cancelled or expired (29,334 ) $ 5.94 Outstanding at end of period 1,603,617 $ 5.02 2.6 years $ 4,344 Exercisable at end of period 1,168,489 $ 4.25 1.2 years $ 2,261
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows: Awards Weighted Outstanding at July 31, 2017 7,436 $ 4.45 Awarded — — Vested (2,562 ) $ (5.51 ) Forfeited (386 ) (5.62 ) Unvested at end of period 4,488 $ 2.97

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Apr. 30, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2018 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,137 — — — $ 18,137 Product revenues — $ 7,415 — — 7,415 Royalty and license fee income — 78 — — 78 18,137 7,493 — — 25,630 Operating costs and expenses: Cost of clinical laboratory services 10,995 — — — 10,995 Cost of product revenues — 3,562 — — 3,562 Research and development — 576 $ 223 — 799 Selling, general and administrative 6,252 2,974 — $ 1,799 11,025 Provision for uncollectible accounts receivable 400 (4 ) — — 396 Legal fee expense 25 19 — 1,607 1,651 Total operating costs and expenses 17,672 7,127 223 3,406 28,428 Operating income (loss) 465 366 (223 ) (3,406 ) (2,798 ) Other income (expense): Interest (22 ) 12 — 237 227 Other 15 2 — — 17 Foreign exchange loss — (462 ) — — (462 ) Income (loss) before income taxes $ 458 $ (82 ) $ (223 ) $ (3,169 ) $ (3,016 ) Depreciation and amortization included above $ 437 $ 358 $ — $ 20 $ 815 Share-based compensation included in above: Selling, general and administrative 26 $ 17 — $ 161 204 Total $ 26 $ 17 $ — $ 161 $ 204 Capital expenditures $ 465 $ 96 $ — $ — $ 561 Three months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 19,584 — — — $ 19,584 Product revenues — $ 7,312 — — 7,312 Royalty and license fee income — 193 — — 193 19,584 7,505 — — 27,089 Operating costs and expenses: Cost of clinical laboratory services 11,334 — — — 11,334 Cost of product revenues — 3,582 — — 3,582 Research and development — 552 $ 214 — 766 Selling, general and administrative 6,118 2,745 — $ 1,671 10,534 Provision for uncollectible accounts receivable 650 (30 ) — — 620 Legal fee expense 4 42 — 466 512 Total operating costs and expenses 18,106 6,891 214 2,137 27,348 Operating income (loss) 1,478 614 (214 ) (2,137 ) (259 ) Other income (expense): Interest (28 ) 12 — 131 115 Other 7 (98 ) — 17 (74 ) Foreign exchange gain — 147 — — 147 Income (loss) before income taxes $ 1,457 $ 675 $ (214 ) $ (1,989 ) $ (71 ) Depreciation and amortization included above $ 390 $ 423 $ — $ 37 $ 850 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 38 $ 23 — $ 146 207 Total $ 40 $ 23 $ — $ 146 $ 209 Capital expenditures $ 483 $ 252 $ — $ — $ 735 Nine months ended April 30, 2018 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 58,001 — — — $ 58,001 Product revenues — $ 21,618 — — 21,618 Royalty and license fee income — 639 — — 639 58,001 22,257 — — 80,258 Operating costs and expenses: Cost of clinical laboratory services 34,767 — — — 34,767 Cost of product revenues — 10,828 — — 10,828 Research and development — 1,690 $ 668 — 2,358 Selling, general and administrative 18,454 8,487 — $ 6,045 32,986 Provision for uncollectible accounts receivable 2,000 (11 ) — — 1,989 Legal fee expense 46 47 — 3,689 3,782 Total operating costs and expenses 55,267 21,041 668 9,734 86,710 Operating income (loss) 2,734 1,216 (668 ) (9,734 ) (6,452 ) Other income (expense): Interest (70 ) 35 — 604 569 Other 32 10 — 44 86 Foreign exchange gain — 143 — — 143 Income (loss) before income taxes $ 2,696 $ 1,404 $ (668 ) $ (9,086 ) $ (5,654 ) Depreciation and amortization included above $ 1,254 $ 1,039 $ — $ 57 $ 2,350 Share-based compensation included in above: Selling, general and administrative 86 $ 61 — $ 470 617 Total $ 86 $ 61 $ — $ 470 $ 617 Capital expenditures $ 1,459 $ 167 $ — $ — $ 1,626 Nine months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 56,979 — — — $ 56,979 Product revenues — $ 21,721 — — 21,721 Royalty and license fee income — 933 — — 933 56,979 22,654 — — 79,633 Operating costs and expenses: Cost of clinical laboratory services 33,282 — — — 33,282 Cost of product revenues — 10,411 — — 10,411 Research and development — 1,695 $ 376 — 2,071 Selling, general and administrative 17,967 8,596 — $ 6,683 33,246 Provision for uncollectible accounts receivable 1,910 58 — — 1,968 Legal fee expense 105 70 — 1,079 1,254 Total operating costs and expenses 53,264 20,830 376 7,762 82,232 Operating income (loss) 3,715 1,824 (376 ) (7,657 ) (2,599 ) Other income (expense): Interest (85 ) 34 — 291 240 Other 126 (98 ) — 41 69 Foreign exchange loss — (308 ) — — (308 ) Income (loss) before income taxes $ 3,756 $ 1,452 $ (376 ) $ (7,430 ) $ (2,598 ) Depreciation and amortization included above $ 1,185 $ 1,432 $ — $ 75 $ 2,692 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 74 $ 49 — $ 473 596 Total $ 79 $ 49 $ — $ 473 $ 601 Capital expenditures $ 1,070 $ 354 $ — $ — $ 1,424

Basis of Presentation (Details)

Basis of Presentation (Details)	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Sales Revenue, Net [Member] | Clinical Labs [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage	40.00%	38.00%	39.00%	38.00%

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Unvested Restricted Stock [Member] | In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	431,000		694,000
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		987,000		865,000
Outstanding Options [Member] | Out of the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	581,000	0	194,000	165,000

Supplemental disclosure for s28

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Jul. 31, 2017
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Income Taxes Paid	$ 65	$ 1,021
Interest Paid	61	99
Installment Loans Financed Amount	$ 0	69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	615,624
Stock Issued During Period, Value, Employee Benefit Plan	$ 782	$ 724	$ 724
Officer [Member]
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	340,898
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ 1,014

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Schedule of inventory, current [Abstract]
Raw materials	$ 817	$ 852
Work in process	2,065	1,905
Finished products	4,396	4,290
	$ 7,278	$ 7,047

Goodwill and intangible asset30

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Jul. 31, 2017
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years
Clinical Labs [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452

Goodwill and intangible asset31

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Indefinite-lived Intangible Assets [Line Items]
July 31, 2017	$ 27,436
July 31, 2017	24,541
July 31, 2017	2,895
Amortization expense	742	$ 1,140
Amortization expense	742	$ 1,140
April 30, 2018	27,438
April 30, 2018	25,289
April 30, 2018	2,149
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2017	27,436
July 31, 2017	(24,541)
July 31, 2017	2,895
Amortization expense	(742)
Amortization expense	(742)
Foreign currency translation	2
Foreign currency translation	(6)
Foreign currency translation	(4)
April 30, 2018	27,438
April 30, 2018	(25,289)
April 30, 2018	$ 2,149

Goodwill and intangible asset32

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,438	$ 27,436
Finite-lived intangible assets, Accumulated Amortization	(25,289)	(24,541)
Finite-lived intangible assets, Net	2,149	2,895
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,971)	(10,951)
Finite-lived intangible assets, Net	56	76
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,892	11,881
Finite-lived intangible assets, Accumulated Amortization	(9,799)	(9,083)
Finite-lived intangible assets, Net	2,093	2,798
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,010	1,011
Finite-lived intangible assets, Accumulated Amortization	(1,010)	(1,011)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	492	484
Finite-lived intangible assets, Accumulated Amortization	(492)	(463)
Finite-lived intangible assets, Net		21
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	3,017	3,033
Finite-lived intangible assets, Accumulated Amortization	$ (3,017)	$ (3,033)

Goodwill and intangible asset33

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	9 Months Ended
	Apr. 30, 2018
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	2 years 6 months
Customer Relationships [Member] | Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Customer Relationships [Member] | Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	1 year 6 months

Accrued Liabilities (Details)

Accrued Liabilities (Details) $ in Thousands	Apr. 30, 2018USD ($)
Payables and Accruals [Abstract]
Accrued Legal Settlement Current	$ 400

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 4,343	$ 4,092
Legal fee expense	2,401	599
Professional fees	764	442
Research and development		143
Other	2,287	1,444
	$ 9,795	$ 6,720

Other Liabilities (Details)

Other Liabilities (Details) $ in Thousands	Apr. 30, 2018USD ($)
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Capital Leases, Future Minimum Payments, Interest Included in Payments	$ 75
Capital Lease Obligations	570
Capital Lease Obligations, Current	173
Long-term Debt	44
Long-term Debt, Current Maturities	$ 37

Other Liabilities (Details) - S

Other Liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Apr. 30, 2018	Jul. 31, 2017
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 404	$ 983
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	397	551
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities		410
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 7	$ 22

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	9 Months Ended		12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Jul. 31, 2017	Dec. 31, 2014
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01
Percentage of Commission Payable on Equity Offering	3.00%
Maximum Offering Price Under Sales Agreement	$ 20,000,000			$ 20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	615,624
Excess Tax Benefit from Share-based Compensation, Financing Activities	$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	14 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 22,000	19,000
Stock Issued During Period, Value, Employee Benefit Plan	782,000	$ 724,000	$ 724,000
Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	22 months
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	5,000,000		3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	2,266,800
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Authorized Common Stock That May Be Issued And Sold Under Sales Agreement	$ 19,150,000
Securities That May Be Sold Under The Agreement	$ 150,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	274,726
Treasury Stock, Shares, Acquired (in Shares)	340,898
Treasury Stock, Value, Acquired, Cost Method	$ 4,000
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares)	37,580	91,541
Treasury Stock [Member]
Stockholders' Equity (Details) [Line Items]
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ (1,014,000)
Stock Issued During Period, Value, Employee Benefit Plan	$ 1,014,000
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares)	(106,911)
Officer [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	340,898
Treasury Stock, Shares, Acquired (in Shares)	106,911
Treasury Stock, Value, Acquired, Cost Method	$ 1,014,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 204	$ 209	$ 617	$ 601
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	202	204	609	586
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 2	$ 5	$ 8	$ 15

Stockholders' Equity (Details40

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 204	$ 209	$ 617	$ 601
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement		2		5
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 204	$ 207	$ 617	$ 596

Stockholders' Equity (Details41

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2018USD ($)$ / sharesshares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2017 | shares	2,130,995
Outstanding at July 31, 2017 | $ / shares	$ 4.26
Awarded | shares	117,580
Awarded | $ / shares	$ 8.36
Exercised | shares	(615,624)
Exercised | $ / shares	$ 2.99
Exercised | $	$ 5,896
Cancelled or expired | shares	(29,334)
Cancelled or expired | $ / shares	$ 5.94
Outstanding at end of period | shares	1,603,617
Outstanding at end of period | $ / shares	$ 5.02
Outstanding at end of period	2 years 219 days
Outstanding at end of period | $	$ 4,344
Exercisable at end of period | shares	1,168,489
Exercisable at end of period | $ / shares	$ 4.25
Exercisable at end of period	1 year 73 days
Exercisable at end of period | $	$ 2,261

Stockholders' Equity (Details42

Stockholders' Equity (Details) - Schedule of restricted stock awards	9 Months Ended
	Apr. 30, 2018$ / sharesshares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2017 | shares	7,436
Outstanding at July 31, 2017 | $ / shares	$ 4.45
Vested | shares	(2,562)
Vested | $ / shares	$ (5.51)
Forfeited | shares	(386)
Forfeited | $ / shares	$ (5.62)
Unvested at end of period | shares	4,488
Unvested at end of period | $ / shares	$ 2.97

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		5 Months Ended	7 Months Ended	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Dec. 31, 2017	Jul. 31, 2018	Apr. 30, 2018	Apr. 30, 2017
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			35.00%
Effective Income Tax Rate Reconciliation, Percent	0.00%				24.10%
Income Tax Expense (Benefit) (in Dollars)		$ 0			$ (1,097)	$ 0
Scenario, Plan [Member]
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				21.00%
Alternate Minimum Tax [Member]
Income taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Amount (in Dollars)					$ 1,100

Segment reporting (Details)

Segment reporting (Details)	9 Months Ended
	Apr. 30, 2018
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Segment Reporting Information [Line Items]
Revenues	$ 25,630	$ 27,089	$ 80,258	$ 79,633
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Operating income (loss)	(2,798)	(259)	(6,452)	(2,599)
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Share-based compensation	204	209	617	601
Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	207	617	596
Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Clinical Labs [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Selling, general and administrative	6,252	6,118	18,454	17,967
Provision for uncollectible accounts receivable	400	650	2,000	1,910
Legal fee expense	25	4	46	105
Total operating costs and expenses	17,672	18,106	55,267	53,264
Operating income (loss)	465	1,478	2,734	3,715
Interest	(22)	(28)	(70)	(85)
Other	15	7	32	126
Income (loss) before income taxes	458	1,457	2,696	3,756
Depreciation and amortization included above	437	390	1,254	1,185
Capital expenditures	465	483	1,459	1,070
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	26	38	86	74
Clinical Labs [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	26	40	86	79
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	7,493	7,505	22,257	22,654
Research and development	576	552	1,690	1,695
Selling, general and administrative	2,974	2,745	8,487	8,596
Provision for uncollectible accounts receivable	(4)	(30)	(11)	58
Legal fee expense	19	42	47	70
Total operating costs and expenses	7,127	6,891	21,041	20,830
Operating income (loss)	366	614	1,216	1,824
Interest	12	12	35	34
Other	2	(98)	10	(98)
Foreign exchange gain (loss)	(462)	147	143	(308)
Income (loss) before income taxes	(82)	675	1,404	1,452
Depreciation and amortization included above	358	423	1,039	1,432
Capital expenditures	96	252	167	354
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	17	23	61	49
Life Sciences [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	17	23	61	49
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	223	214	668	376
Total operating costs and expenses	223	214	668	376
Operating income (loss)	(223)	(214)	(668)	(376)
Income (loss) before income taxes	(223)	(214)	(668)	(376)
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	1,799	1,671	6,045	6,683
Legal fee expense	1,607	466	3,689	1,079
Total operating costs and expenses	3,406	2,137	9,734	7,762
Operating income (loss)	(3,406)	(2,137)	(9,734)	(7,657)
Interest	237	131	604	291
Other		17	44	41
Income (loss) before income taxes	(3,169)	(1,989)	(9,086)	(7,430)
Depreciation and amortization included above	20	37	57	75
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	161	146	470	473
Other Segments [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	161	146	470	473
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	25,630	27,089	80,258	79,633
Research and development	799	766	2,358	2,071
Selling, general and administrative	11,025	10,534	32,986	33,246
Provision for uncollectible accounts receivable	396	620	1,989	1,968
Legal fee expense	1,651	512	3,782	1,254
Total operating costs and expenses	28,428	27,348	86,710	82,232
Operating income (loss)	(2,798)	(259)	(6,452)	(2,599)
Interest	227	115	569	240
Other	17	(74)	86	69
Foreign exchange gain (loss)	(462)	147	143	(308)
Income (loss) before income taxes	(3,016)	(71)	(5,654)	(2,598)
Depreciation and amortization included above	815	850	2,350	2,692
Capital expenditures	561	735	1,626	1,424
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	207	617	596
Consolidated [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	204	209	617	601
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation		2		5
Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Clinical Laboratory Services [Member] | Clinical Labs [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Clinical Laboratory Services [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	18,137	19,584	58,001	56,979
Cost of Revenues	10,995	11,334	34,767	33,282
Product [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Product [Member] | Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Product [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	7,415	7,312	21,618	21,721
Cost of Revenues	3,562	3,582	10,828	10,411
Royalty and License Fees [Member]
Segment Reporting Information [Line Items]
Revenues	78	193	639	933
Royalty and License Fees [Member] | Life Sciences [Member]
Segment Reporting Information [Line Items]
Revenues	78	193	639	933
Royalty and License Fees [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	$ 78	$ 193	$ 639	$ 933

Contingencies (Details)

Contingencies (Details)	9 Months Ended
	Apr. 30, 2018
Loss Contingency [Abstract]
Number Of Pending Cases	7
Loss Contingency Number Of New Defendants	2